185 related articles for article (PubMed ID: 16594594)
1. A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP-HDC) for canine lymphoma.
Frimberger AE; Moore AS; Rassnick KM; Cotter SM; O'Sullivan JL; Quesenberry PJ
J Vet Intern Med; 2006; 20(2):355-64. PubMed ID: 16594594
[TBL] [Abstract][Full Text] [Related]
2. Thirteen-week dose-intensifying simultaneous combination chemotherapy protocol for malignant lymphoma in dogs.
Zenker I; Meichner K; Steinle K; Kessler M; Hirschberger J
Vet Rec; 2010 Nov; 167(19):744-8. PubMed ID: 21257510
[TBL] [Abstract][Full Text] [Related]
3. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma.
Zemann BI; Moore AS; Rand WM; Mason G; Ruslander DM; Frimberger AE; Wood CA; L'Heureux DA; Gliatto J; Cotter SM
J Vet Intern Med; 1998; 12(6):465-70. PubMed ID: 9857340
[TBL] [Abstract][Full Text] [Related]
4. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol.
Simon D; Nolte I; Eberle N; Abbrederis N; Killich M; Hirschberger J
J Vet Intern Med; 2006; 20(4):948-54. PubMed ID: 16955821
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-induced neutropenia is associated with prolonged remission duration and survival time in canine lymphoma.
Wang SL; Lee JJ; Liao AT
Vet J; 2015 Jul; 205(1):69-73. PubMed ID: 26004824
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma.
Moore AS; Cotter SM; Rand WM; Wood CA; Williams LE; London CA; Frimberger AE; L'Heureux DA
J Vet Intern Med; 2001; 15(4):348-54. PubMed ID: 11467592
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of a high-dose chemotherapy protocol with no maintenance therapy for dogs with lymphoma.
Chun R; Garrett LD; Vail DM
J Vet Intern Med; 2000; 14(2):120-4. PubMed ID: 10772481
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Tolerability of Combination Chemotherapy with Mitoxantrone and Dacarbazine in Dogs with Lymphoma.
Intile JL; Rassnick KM; Al-Sarraf R; Chretin JD
J Am Anim Hosp Assoc; 2019; 55(2):101-109. PubMed ID: 30653362
[TBL] [Abstract][Full Text] [Related]
9. Influence of asparaginase on a combination chemotherapy protocol for canine multicentric lymphoma.
Jeffreys AB; Knapp DW; Carlton WW; Thomas RM; Bonney PL; Degortari A; Lucroy MD
J Am Anim Hosp Assoc; 2005; 41(4):221-6. PubMed ID: 15995158
[TBL] [Abstract][Full Text] [Related]
10. Phase I dose escalation of single-agent vinblastine in dogs.
Bailey DB; Rassnick KM; Kristal O; Chretin JD; Balkman CE
J Vet Intern Med; 2008; 22(6):1397-402. PubMed ID: 19000250
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and toxicity of carboplatin and cytarabine chemotherapy for dogs with relapsed or refractory lymphoma (2000-2013).
Gillem J; Giuffrida M; Krick E
Vet Comp Oncol; 2017 Jun; 15(2):400-410. PubMed ID: 26463827
[TBL] [Abstract][Full Text] [Related]
12. Comparison of COAP and UW-19 protocols for dogs with multicentric lymphoma.
Hosoya K; Kisseberth WC; Lord LK; Alvarez FJ; Lara-Garcia A; Kosarek CE; London CA; Couto CG
J Vet Intern Med; 2007; 21(6):1355-63. PubMed ID: 18196747
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma.
Garrett LD; Thamm DH; Chun R; Dudley R; Vail DM
J Vet Intern Med; 2002; 16(6):704-9. PubMed ID: 12465768
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007).
Flory AB; Rassnick KM; Erb HN; Garrett LD; Northrup NC; Selting KA; Phillips BS; Locke JE; Chretin JD
J Am Vet Med Assoc; 2011 Feb; 238(4):501-6. PubMed ID: 21320021
[TBL] [Abstract][Full Text] [Related]
15. Autologous marrow transplantation as consolidation therapy for canine lymphoma: efficacy and toxicity of various regimens of total body irradiation.
Deeg HJ; Appelbaum FR; Weiden PL; Hackman RC; Graham TC; Storb RC
Am J Vet Res; 1985 Sep; 46(9):2016-8. PubMed ID: 3901841
[TBL] [Abstract][Full Text] [Related]
16. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
Wheeler C; Antin JH; Churchill WH; Come SE; Smith BR; Bubley GJ; Rosenthal DS; Rappaport JM; Ault KA; Schnipper LE
J Clin Oncol; 1990 Apr; 8(4):648-56. PubMed ID: 2313334
[TBL] [Abstract][Full Text] [Related]
17. Sequential low-dose rate half-body irradiation and chemotherapy for the treatment of canine multicentric lymphoma.
Lurie DM; Gordon IK; Théon AP; Rodriguez CO; Suter SE; Kent MS
J Vet Intern Med; 2009; 23(5):1064-70. PubMed ID: 19627472
[TBL] [Abstract][Full Text] [Related]
18. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study.
Snyder MJ; Johnson DB; Daly MB; Giguere JK; Harman GH; Harden EA; Johnson RA; Leff RS; Mercier RJ; Messerschmidt GL
Bone Marrow Transplant; 1994 Oct; 14(4):595-600. PubMed ID: 7858534
[TBL] [Abstract][Full Text] [Related]
19. Impact of chemotherapeutic dose intensity and hematologic toxicity on first remission duration in dogs with lymphoma treated with a chemoradiotherapy protocol.
Vaughan A; Johnson JL; Williams LE
J Vet Intern Med; 2007; 21(6):1332-9. PubMed ID: 18196744
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 3 protocols for treatment after induction of remission in dogs with lymphoma.
Rassnick KM; McEntee MC; Erb HN; Burke BP; Balkman CE; Flory AB; Kiselow MA; Autio K; Gieger TL
J Vet Intern Med; 2007; 21(6):1364-73. PubMed ID: 18196748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
